Article
The new technology has the potential to be safer with the delivery of micropulses of BSS, which results in littleor no increase in temperature or vibration inside the eye.
Kalaris and AlloVir Inc. complete merger
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Staying the course in shifting winds
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
How COVID-19 shifted ophthalmologist-patient communication
Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200